NCT03220165已完成1 期
An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Mass Balance of [14C] MGL-3196
研究概览
简要总结
The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Voluntarily consents to participate and provides written informed consent.
- •Is a male.
- •Is between 18 and 55 years of age (inclusive).
- •Has a body mass index (BMI) between 18 and 32 kg/m2 (inclusive), and weighs a minimum of 50 kg.
- •Is willing and able to remain in the study unit for the entire duration of the confinement periods
- •Is willing to eat entire meals and snacks provided during confinement at the research facility; and understand that the diet will include foods with high fiber content and possibly prune juice.
- •Is willing to have collected all urine and fecal samples for the duration of the study period as required.
- •Is willing to use a waterless commode located in a designated dry room for urine and feces collection for the duration of the study period as required.
- •Is willing to abstain from showering for the first 72 hours after administration of [14C] MGL-
- •After the restriction from showering is lifted, must be willing to provide a urine sample prior to showering for the remainder of the confinement period.
排除标准
- •History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
- •A clinically significant abnormal finding on the physical exam, medical history, electrocardiogram (ECG), or clinical laboratory results at screening.
- •Thyroid stimulating hormone test at screening outside the normal range. Repeat testing is allowed once at the discretion of the Investigator.
- •Current or recent (<6 months) hepatobiliary disease; or AST, ALT or direct bilirubin greater than the upper limit of reference range at screening. Repeat testing is allowed once at the discretion of the Investigator.
- •Elevated CK at screening (one repeat test allowed).
- •History of Gilbert's syndrome.
- •Pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study drug.
- •Abnormal screening ECG: including machine-read QTcF >450 msec (confirmed by manual over read), QRS >110 msec, intermittent bundle branch block, frequent premature atrial or premature ventricular contractions, or any rhythm other than normal sinus rhythm which is interpreted by the Investigator to be clinically significant.
- •History of sensitivity to a similar study drug (e.g., Karo Bio KB2115 or Metabasis MB7811), or a history of important drug or other allergy (except for untreated, asymptomatic seasonal allergies at time of dosing) unless deemed not clinically significant by the Investigator.
- •History of sensitivity to thyroid medication.
- •Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
- •Has participated in a standard radiolabeled clinical trial within the last 12 months prior to the first dose of study medication or a micro tracer clinical trial within the last 3 months prior to the first dose of study medication.
- •Has participated in another clinical trial (randomized subjects only) within 30 days prior to the first dose of study medication.
- •Use of any over-the-counter (OTC) medication (including nutritional or dietary supplements, herbal preparations, vitamins, or acetaminophen) within 7 days prior to the first dose of study medication until the end of study visit without evaluation and approval by the Investigator.
- •Use of any prescription medication from 14 days prior to the first dose of study medication until the end-of-study visit without evaluation and approval by the Investigator.
- •Has been treated with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine) within 30 days prior to the first dose of study medication, and that, in the Investigator's judgment, may impact subject safety or the validity of the study results.
- •Blood or plasma donation within 30 days prior to the first dose of study medication until the end-of-study visit. It is recommended that blood/plasma donations not be made for at least 30 days after the end-of-study visit.
- •Smoking or use of tobacco- or nicotine-containing products within 60 days prior to the first dose of study medication until the end-of-study visit.
- •Consumption of beverages or foods that contain grapefruit, poppy seeds, broccoli, Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine from 48 hours prior to the first dose of study medication until the end-of-study visit. Subjects will be instructed not to consume any of the above products; however, allowance for an isolated single incidental consumption may be evaluated and approved by the study Investigator based on the potential for interaction with the study drug.
- •Has any prior history of substance abuse or treatment (including alcohol).
- •History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months prior to screening.
- •Use of alcohol within 24 hours prior to dosing and throughout the study.
- •Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates) or cotinine.
- •Has a positive test for hepatitis B surface antigen, hepatitis C antibody, or human immunodeficiency virus (HIV) at screening or has been previously treated for hepatitis B, hepatitis C, or HIV infection.
- •Excessive caffeine intake (>3 cups of coffee/day or equivalent).
- •Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical disease (e.g., infectious disease) must not be enrolled.
- •Any other sound medical, psychiatric, and /or social reason as determined by the Investigator.
- •Has irregular bowel habits. ("Irregular" being defined for the purpose of this study as NOT having a bowel movement at least every 2 days.)
- •Has been exposed to radiation, including dental or medical imaging such as X-ray or tomography, in the 6 months prior to dose administration.
- •Has been involved in an occupation that requires monitoring for radiation exposure (eg, X-ray technician).
研究组 & 干预措施
Treatment
Experimental
MGL-3196
干预措施: MGL-3196 (Drug)
结局指标
主要结局
Mass Balance of [14C] MGL-3196
时间窗: Approximately 10 Days
Measurement of the total radioactivity collected from blood, urine, and feces
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsHepatic ImpairmentNASH - Nonalcoholic SteatohepatitisCirrhosis, LiverNCT04643795Madrigal Pharmaceuticals, Inc.87
已完成
1 期
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]NXL104HealthyNCT01448395Pfizer6
已完成
1 期
Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male VolunteersHealthyNCT02142920Pfizer6
已完成
1 期
A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.Pulmonary Disease, Chronic ObstructiveNCT01286831GlaxoSmithKline6
已完成
1 期
A Study Investigating Lu AG06466 in Healthy MenHealthy VolunteersNCT05201092H. Lundbeck A/S6